As infertility rates rise and reproductive choices evolve, fertility care today demands far more than medical expertise—it requires empathy, ethical clarity, and technological precision.
Dr Hrishikesh Pai, Founder & Medical Director of Bloom IVF Group, has been at the forefront of transforming assisted reproductive medicine in India and beyond. Recognized as a global leader in IVF and reproductive health, Dr Pai has built a model that seamlessly integrates evidence-based protocols with compassionate, patient-centric care.
In this conversation, he shares insights on balancing innovation with responsibility, handling complex infertility cases, mentoring the next generation of fertility specialists, and envisioning how advancements in AI and reproductive science will shape the future of fertility care in India over the next decade.
1. Fertility treatment is often emotionally overwhelming for couples. How do you ensure that compassionate care remains central to clinical excellence?
At Bloom IVF, we believe clinical excellence and compassionate care are not separate pillars they are interdependent. Infertility treatment is not just a medical journey; it is deeply emotional, often accompanied by anxiety, social pressure, and financial concerns. Our approach begins with active listening. Every couple undergoes detailed counseling before investigations even begin, ensuring they understand the process, timelines, and realistic expectations.
We have integrated psychological counseling into our treatment pathway, so emotional well-being is addressed alongside medical protocols. Our clinicians and embryologists are trained to communicate transparently, especially during sensitive stages such as cycle cancellation or implantation failure. By combining evidence-based medicine with empathy driven communication, we ensure that patients feel supported not just treated
2. Bloom IVF has become a preferred destination for both Indian and international patients. What differentiates your approach in terms of outcomes and patient experience?
Our differentiation lies in a structured, protocol-driven system combined with personalized treatment plans. While we follow globally benchmarked clinical protocols, no two patients receive identical treatment. Detailed diagnostic mapping, individualized ovarian stimulation plans, and continuous monitoring allow us to optimize outcomes.
For international patients, we provide end-to-end coordination from virtual consultations and treatment planning to accommodation support and post-treatment follow-ups. Our laboratory infrastructure adheres to international quality standards, and we invest heavily in embryology excellence. Ultimately, it is the balance between high success rates, ethical transparency, and a seamless patient journey that makes us a trusted choice.
3. With advancements like embryo vitrification and laser-assisted hatching improving success rates, how do you assess when technology truly enhances results versus when it is simply a trend?
In reproductive medicine, technology must serve evidence not marketing. Procedures such as embryo vitrification and laser-assisted hatching have demonstrated clear benefits in specific patient categories. For example, vitrification has revolutionized embryo freezing by significantly improving post-thaw survival rates. However, we do not apply advanced techniques universally.
Each intervention is recommended based on scientific data, patient profile, age, ovarian reserve, and previous cycle history. We continuously review global research and audit our own clinical outcomes. If a technology does not demonstrate measurable improvement in implantation or live birth rates for a particular indication, we do not incorporate it routinely. Responsible adoption ensures that innovation enhances care rather than complicates it.
4. What are the most complex infertility cases you see today, and how has innovation expanded treatment possibilities for such patients?
Today, we are seeing increasing cases of diminished ovarian reserve in younger women, severe male factor infertility, recurrent implantation failure, and fertility challenges linked to lifestyle disorders. Delayed parenthood is also contributing to age-related infertility complexities.
Innovations in advanced sperm retrieval techniques, genetic screening, and embryo culture systems have significantly expanded possibilities. Patients who previously had minimal chances of conception now have viable pathways to parenthood. In complex cases, multidisciplinary collaboration including endocrinologists, genetic counselors, and andrologists plays a crucial role in improving outcomes.
5. As a mentor and academic contributor, how are you preparing the next generation of fertility specialists to uphold global standards of care?
Reproductive medicine demands both technical precision and ethical responsibility. Through academic workshops, live training modules, and structured fellowships, we emphasize protocol adherence, laboratory discipline, and patient communication skills.
Young specialists are trained not only in procedures but also in decision-making frameworks when to intervene and when to step back. We also stress outcome auditing, documentation, and continuous learning through global research updates. Building competence with integrity is essential for sustaining trust in this field.
6. Looking ahead, what key shifts in medical science, technology, or society do you believe will redefine fertility care in India over the next decade?
Over the next decade, fertility care in India will be shaped by three major shifts: earlier fertility awareness, AI-driven laboratory optimization, and broader societal acceptance of assisted reproduction.
We anticipate increased use of predictive analytics in embryo selection, improved cryopreservation techniques, and greater integration of fertility preservation for both medical and elective reasons. At the same time, societal attitudes are evolving single parenthood, delayed marriages, and career-focused lifestyles are reshaping reproductive planning.
The future of fertility care will not only be about improving success rates but also about expanding access, affordability, and awareness. The ultimate goal will be to make advanced reproductive care both scientifically robust and emotionally supportive for every patient who seeks it.
